iMBIORAY
Latest round
- Series A
Last raised
- Jan 2025
Total raised
- $36M
Investors
- 10
About iMBIORAY
, trading under the name iMBIORAY, operates as a medical company that focuses on the research and development of tumor drugs. Zhenwei Miao, the founder and CEO of the company, once served as chief scientist of Enanta and senior chemical director of Ambrx. The company provides cancer and immune diseases treatment, and tumor cell immunotherapy drug. The company focuses on CAR-NK cell therapy, bispecific antibodies and AIC drugs R&D. The company develops bispecific antibody technology and antibody conjugation (ADC) technology. The company's products include CAR-raNK IBR733 and IBR854, and tiNK cell therapy. Products can be used in tumor immunotherapy, immune diseases, chronic diseases and CNS diseases. The company’s revenue is generated by the development and potential licensing of immunotherapy drug candidates and cell therapy platforms. It also earns income through strategic research collaborations and partnerships with other pharmaceutical entities to co-develop bispecific antibodies and antibody-drug conjugate (ADC) technologies.
Who invested in iMBIORAY
10 investors across 2 rounds
See all investors in iMBIORAY
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about iMBIORAY
Who invested in iMBIORAY?
iMBIORAY has 10 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has iMBIORAY raised?
iMBIORAY has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did iMBIORAY last raise money?
iMBIORAY's most recent round on record is a Series A, in Jan 2025.
What does iMBIORAY do?
, trading under the name iMBIORAY, operates as a medical company that focuses on the research and development of tumor drugs.
Where is iMBIORAY headquartered?
iMBIORAY is headquartered in Hangzhou, China.
Which VCs invest in companies like iMBIORAY?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at iMBIORAY's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like iMBIORAY? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.